Clinical Trial: RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited

Brief Summary: The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Detailed Summary:
Sponsor: Repligen Corporation

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Repligen Corporation

Dates:
Date Received: May 7, 2003
Date Started:
Date Completion:
Last Updated: August 4, 2005
Last Verified: August 2005